Chansky K, Sculier JP, Crowley JJ, et al. International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009;4(7):792-801.
Perez-Ramirez C, Canadas-Garre M, Robles AI, et al. Liquid biopsy in early stage lung cancer. Transl Lung Cancer Res 2016; 5(5):517-24
Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29.
Sholl LM, Aisner DL, Allen TC, et al. Liquid biopsy in lung cancer: A perspective from members of the pulmonary pathology society. Arch Pathol Lab Med 2016;140(8):825-9.
Mino-Kenudson M. Rebuttal from Dr. Mino-Kenudson. Transl Lung Cancer Res 2016;5(4):430-2
Zhang Z, Ramnath N, Nagrath S. Current status of CTCs as liquid biopsy in lung cancer and future directions. Front Oncol 2015;5:209.
Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res 2014;3(4):242-9
Al-Kattan K, Sepsas E, Fountain SW, et al. Disease recurrence after resection for stage I lung cancer. Eur J Cardiothorac Surg 1997;12(3):380-4.
Ilie M, Hofman P. Pros: Can tissue biopsy be replaced by liquid biopsy? Transl Lung Cancer Res 2016;5(4):420-3.
Zhang J, Fujimoto J, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion. Science 2014;346(6206):256-9.
Stewart EL, Tan SZ, Liu G, et al. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLS patients with EGFR mutations- a review. Transl Lung Cancer Res 2015; 4(10):67-81.
Chen YM. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer. J Chin Med Assoc 2013;76:249-57.
Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011;29(Suppl) abstract CRA7506.
Shiau CJ, Babwah JP, da Cunha Santos G, et al. Sample features associated with success rates in population-based EGFR mutation testing. J Thorac Oncol 2014;9(7):947-56.
Morgensztern D, Politi K, Herbst RS. EGFR Mutations in Non-Small-Cell Lung Cancer: Find, Divide, and Conquer. JAMA Oncol 2015;1(2):146-8.
Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25(5):587-95.
Ma C, Wei S, Song Y. T790 and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis 2011;3(1):10-8.
Wong SQ, Li J, Tan AY, et al. The CANCER 2015 Cohort. Sequence artefacts in a prospective series of for formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med Genomics 2014;7:23.
